This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elder, D. E. Articles by Herlyn, M. Search for Related Content PubMed PubMed Citation Articles by Elder, D. E. Articles by Herlyn, M.

Antigenic Profile of Tumor Progression Stages in Human Melanocytic Nevi and Melanomas¹

Pigmented Lesion Study Group, Hospital of the University of Pennsylvania [D. E. E., W. H. C., R. S.], The Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine [D. E. E.], and The Wistar Institute of Anatomy and Biology, [U. R., J. T., F. C., M. H.] Philadelphia, Pennsylvania 19104

Sixteen monoclonal antibodies that were obtained after immunization of BALB/c mice with intact melanoma cells or extracts of melanoma cells were tested for reactivity with normal and malignant melanocytic cells in situ, using an immunoperoxidase technique on frozen tissue sections. Sections representing six histopathologically defined stages of tumor progression, ranging from normal melanocytes to highly malignant metastatic lesions, were used. Thirteen monoclonal antibodies (MAbs) did not stain normal melanocytes in situ, whereas three MAbs weakly stained between 1 and 12.5% of melanocytes in 6–22% of the skin sections examined. MAb B 73.1, which was produced by immunization of mice with human natural killer cells and which binds to the Fc receptor of natural killer cells and granulocytes, reacted exclusively with malignant cells that represent the last two stages of tumor progression, vertical growth phase (VGP) primary melanoma and metastatic melanoma. All other antibodies showed variable reactivity with benign proliferative lesions or radial growth phase (RGP), an early stage of primary melanoma. Staining by MAbs that were reactive with gangliosides, unknown antigens, receptors, and two proteins (120/94 kDa protein and 250 kDa glycoprotein) showed a gradual increase in subsequent stages of tumor progression. Two steps in tumor progression were characterized by significant quantitative changes in the expression of antigens detected by the MAbs used in this study. First, mature nevus cells showed significantly higher reactivity with a panel of six MAbs, when compared to normal melanocytes. Second, a separate panel of six MAbs discriminated between RGP and VGP primary melanoma cells. No significant differences in antigen expression were found between dysplastic nevus cells and RGP melanoma, except that some antigens (nerve growth factor receptor and G_D2/G_D3 gangliosides) appear to be expressed at lower levels in RGP lesions, nor did VGP primary and metastatic melanomas show significant differences in antigen expression. These results suggest that (a) tumor progression of melanocytic cells in vivo is accompanied by significant quantitative differences in the expression of antigens, (b) some of the antigens examined here are associated with biologically aggressive malignant lesions but not normal or premalignant melanocytic cells, and (c) RGP primary melanoma cells are antigenically more similar to nevus cells than to VGP primary melanoma cells.

¹ Supported by Grants CA-25874, CA-10815, CA-44877, and Ca-25298 from the NIH.

² To whom requests for reprints should be addressed, at The Pigmented Lesion Study Group, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.

Received 1/ 5/89. Revised 6/ 6/89. Accepted 6/14/89.

This article has been cited by other articles:

				H. Wang, R. B. Presland, and M. Piepkorn A Search for CDKN2A/p16INK4a Mutations in Melanocytic Nevi From Patients With Melanoma and Spouse Controls by Use of Laser-Captured Microdissection Arch Dermatol, February 1, 2005; 141(2): 177 - 180. [Abstract] [Full Text] [PDF]

				K. L. Amend, J. T. Elder, L. P. Tomsho, J. D. Bonner, T. M. Johnson, J. Schwartz, M. Berwick, and S. B. Gruber EGF Gene Polymorphism and the Risk of Incident Primary Melanoma Cancer Res., April 15, 2004; 64(8): 2668 - 2672. [Abstract] [Full Text] [PDF]

				E. C. McGary, A. Heimberger, L. Mills, K. Weber, G. W. Thomas, M. Shtivelband, D. C. Lev, and M. Bar-Eli A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells In Vivo Clin. Cancer Res., December 15, 2003; 9(17): 6560 - 6566. [Abstract] [Full Text] [PDF]

				K. Bernard, E. Litman, J. L. Fitzpatrick, Y. G. Shellman, G. Argast, K. Polvinen, A. D. Everett, K. Fukasawa, D. A. Norris, N. G. Ahn, et al. Functional Proteomic Analysis of Melanoma Progression Cancer Res., October 15, 2003; 63(20): 6716 - 6725. [Abstract] [Full Text] [PDF]

				R. A. Gatenby and B. R. Frieden Application of Information Theory and Extreme Physical Information to Carcinogenesis Cancer Res., July 1, 2002; 62(13): 3675 - 3684. [Abstract] [Full Text] [PDF]

				B. L. Goodwin, H. Xi, R. Tejiram, D. D. Eason, N. Ghosh, K. L. Wright, U. Nagarajan, J. M. Boss, and G. Blanck Varying Functions of Specific Major Histocompatibility Class II Transactivator Promoter III and IV Elements in Melanoma Cell Lines Cell Growth Differ., June 1, 2001; 12(6): 327 - 335. [Abstract] [Full Text] [PDF]

				D. Fang, J. Hallman, N. Sangha, T. E. Kute, J. A. Hammarback, W. L. White, and V. Setaluri Expression of Microtubule-Associated Protein 2 in Benign and Malignant Melanocytes : Implications for Differentiation and Progression of Cutaneous Melanoma Am. J. Pathol., June 1, 2001; 158(6): 2107 - 2115. [Abstract] [Full Text] [PDF]

				M.-Y. Hsu, F. E. Meier, M. Nesbit, J.-Y. Hsu, P. Van Belle, D. E. Elder, and M. Herlyn E-Cadherin Expression in Melanoma Cells Restores Keratinocyte-Mediated Growth Control and Down-Regulates Expression of Invasion-Related Adhesion Receptors Am. J. Pathol., May 1, 2000; 156(5): 1515 - 1525. [Abstract] [Full Text] [PDF]